Iberet-Folic-500 Special Precautions

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under six years of age. In case of accidental overdose, call a doctor or seek a medical advice immediately.
Iron therapy could induce relapse of erythropoietic protoporphyria. Iron overload has been suggested as being involved in the pathogenesis of porphyria cutanea tarda.
Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B₁₂ is deficient.
Where anemia exists, its nature should be established and underlying causes determined.
Iberet-Folic 500 contains increased amounts (see Description) of folic acid per tablet. Folic acid especially in doses above 0.1 mg daily may obscure pernicious anemia, in that hematologic remission may occur while neurological manifestations remain progressive. Concomitant parenteral therapy with Vitamin B12 may be necessary in patients with deficiency of vitamin B₁₂. Pernicious anemia is rare in women of childbearing age, and the likelihood of its occurrence alone with pregnancy is reduced by impairment of fertility associated with vitamin B₁₂ deficiency.
Caution should be exercised when dosing ascorbic acid in patients with chronic renal failure and in patients receiving acetylsalicylic acid.
Like other oral iron preparations, Iberate-Folic 500 should be stored out of the reach of children to guard against accidental iron poisoning. (See as follows.)
Laboratory tests: In older patients and those with conditions tending to lead to vitamin B_12, depletion, serum B₁₂ levels should be regularly assessed during treatment with Iberet-Folic 500.
False occult blood tests possible.